Main Article Content
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
International Diabetes Association. IDF Diabetes Atlas. 7th ed. 2017. Available from: http://www.diabetesatlas.org/.
Hattori T, Matsubara A, Taniguchi K, Ogura Y. Aldose reductase inhibitor fidarestat attenuates leukocyte-endothelial interactions in experimental diabetic rat retina in vivo. Curr Eye Res. 2010 Feb;35(2):146-54. doi: 10.3109/02713680903447918.
Wilkinson-Berka JL, Wraight C, Werther G. The role of growth hormone, insulin-like growth factor and somatostatin in diabetic retinopathy. Current Medicinal Chemistry. 2006;13(27):3307-3317. doi: 10.2174/092986706778773086.
Cui Y, Xu X, Bi H, et al. Expression modification of uncoupling proteins and MnSOD in retinal endothelial cells and pericytes induced by high glucose: the role of reactive oxygen species in diabetic retinopathy. Exp Eye Res. 2006 Oct;83(4):807-16. doi: 10.1016/j.exer.2006.03.024.
Zhang XL, Wen L, Chen YJ, Zhu Y. Vascular endothelial growth factor up-regulates the expression of intracellular adhesion molecule-1 in retinal endothelial cells via reactive oxygen species, but not nitric oxide. Chin Med J (Engl). 2009 Feb 5;122(3):338-43.
Mohammad G, Kowluru RA. Novel role of mitochondrial matrix metalloproteinase-2 in the development of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2011 Jun 1;52(6):3832-41. doi: 10.1167/iovs.10-6368.
Min SH, Lee TI, Chung YS, Kim HK. Transforming growth factor-α levels in human aqueous humor of glaucomatous, diabetic and uveitic eyes. Korean J Ophthalmol. 2006 Sep;20(3):162-5. doi: 10.3341/kjo.2006.20.3.162.
Yee P, Weymouth AE, Fletcher EL, Vingrys AJ. A Role for Omega-3 Polyunsaturated Fatty Acid Supplements in Diabetic Neuropathy. Invest Ophthalmol Vis Sci. 2010 Mar;51(3):1755-64. doi: 10.1167/iovs.09-3792.
Gustavsson C, Agardh CD, Agardh E. Profile of intraocular tumour necrosis factor-α and interleukin-6 in diabetic subjects with different degrees of diabetic retinopathy. Acta Ophthalmol. 2013 Aug;91(5):445-52. doi: 10.1111/j.1755-3768.2012.02430.x.
Barber J, Gardner TW, Abcouwer SF. The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2011 Feb 28;52(2):1156-63. doi: 10.1167/iovs.10-6293.
Malachkova NV, Kyryliuk ML, Komarovskaya IV. Association between serum resistin level and diabetic retinopathy in obese patients with type 2 diabetes mellitus. J ophthalmol (Ukraine). 2017;(4):9-13. doi: 10.31288/oftalmolzh20174913. (in Russian).
Paranova A, Iliev I, Filipponi M, et al. Insulin resistance and proliferative retinopathy: a cross-sectional, case-control study in 115 patients with type 2 diabetes. J Clin Endocrinol Metab. 2004 Sep;89(9):4371-6. doi: 10.1210/jc.2003-032076.
Gavin S. Tan GS, and Tien YinWong T, authors. Diabetic retinopathy and other ocular complications. In: DeFronzo RA, Ferrannini E, Zimmet P, eds. International Textbook of Diabetes Mellitus. 4th ed. Wiley-Blackwell; 2015. p. 881.
Malachkova N, Komarovskaya I, Kyryliuk M. Blood glucose level and insulin resistance in patients with type 2 diabetic mellitus, diabetic retinopathy and obesity. Mìžnarodnij endokrinologìčnij žurnal. 2017;13(3):27-32. doi: 10.22141/2224-07188.8.131.527.104108.
Pasechnikova NV, Metelicyna IP, Naumenko VA, Beljaev VD. Changes in the level of pro- and anti-inflammatory cytokines in patients with diabetic retinopathy after laser coagulation of the retina. J ophthalmol (Ukraine). 2010;(2):4-7. doi: 10.31288/oftalmolzh2010247.
Gustavsson C, Agardh E, Bengtsson B, Agardh CD. TNF-alpha is an independent serum marker for proliferative retinopathy in type 1 diabetic patients. J Diabetes Complications. 2008 Sep-Oct;22(5):309-16. doi: 10.1016/j.jdiacomp.2007.03.001.
Kato N, Yashima S, Suzuki T, Nakayama Y, Jomori T. Long-term treatment with fidarestat suppresses the development of diabetic retinopathy in STZ-induced diabetic rats. J Diabetes Complications. 2003 Nov-Dec;17(6):374-9. doi: 10.1016/s1056-8727(02)00193-9.
Haurigot V, Villacampa P, Ribera A, et al. Increased intraocular insulin-like growth factor-I triggers blood-retinal barrier breakdown. J Biol Chem. 2009 Aug 21;284(34):22961-9. doi: 10.1074/jbc.M109.014787.
Spijkerman MW, Gall MA, Tarnow L, et al. Endothelial dysfunction and low-grade inflammation and the progression of retinopathy in type 2 diabetes. Diabet Med. 2007 Sep;24(9):969-76. doi: 10.1111/j.1464-5491.2007.02217.x.
Perk J1, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2012 Jul;33(13):1635-701. doi: 10.1093/eurheartj/ehs092.
Serdyuk VN, Ishchenko VA. Morphometric and Biochemical Clusters of Metabolic Syndrome in Type 2 Diabetic Patients at Different Stages of Diabetic Retinopathy. Mìžnarodnij endokrinologìčnij žurnal. 2016;(79):69-74. doi: 10.22141/2224-07184.108.40.2066.86421.
Kyryliuk ML, Serdiuk VM, Pylypenko LYu. Influence of the factors of the progression of diabetics rethinopathy on the concentration of blood fibrinogen at type 2 diabetes as the component of metabolic syndrome. Clinical Endocrinology and Endocrine Surgery. 2017;4(60):64-69. doi.org/10.24026/1818-1384.4(60).2017.118769